“…Monoclonal antibodies such as Infliximab (anti-TNF-α) and Adalimumab have been suggested as secondary lines of treatment for refractory multifocal disseminated lesions or in cases of multiple organ involvement [13,28,56]. In patients diagnosed with inflammatory bowel disease, Infliximab is often the therapeutic drug of choice [28,57,58]. Some reports of treatment with thalidomide and colchicine demonstrate variable responses [5,17,19,59].…”